RenovoRx, Inc.
RNXT · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.53 | 0.08 | -0.08 | 13.28 |
| FCF Yield | -4.77% | -10.88% | -8.50% | -8.30% |
| EV / EBITDA | -13.53 | -5.40 | -7.59 | -5.97 |
| Quality | ||||
| ROIC | -21.80% | -21.49% | -41.51% | -34.24% |
| Gross Margin | 63.98% | 52.28% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.80 | 1.40 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 975,299.79% | 871,437.34% | 621,346.50% | 350,239.81% |
| Free Cash Flow Growth | 31.95% | -38.53% | -11.30% | 4.48% |
| Safety | ||||
| Net Debt / EBITDA | 4.50 | 4.60 | 2.39 | 3.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -319.89 | -815.29 | 90.00 | 0.00 |